Genfit Valuation Multiples

Genfit Overview

About Genfit

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Founded

1999

HQ

Employees

180

Website

genfit.com

Sectors

BiopharmaceuticalsDiagnostics & GenomicsBioTech

Financials (LTM)

Revenue: $83M

EBITDA: ($24M)

EV

$600M

Valuation Multiples

Multiples.vc

Start free trial

Genfit Financials

Genfit reported last 12-month revenue of $83M and negative EBITDA of ($24M).

In the same LTM period, Genfit generated ($24M) in EBITDA losses and had net loss of ($70M).

Genfit P&L

In the most recent fiscal year, Genfit reported revenue of $82M and EBITDA of ($35M).

Genfit expects next 12-month revenue of XXX and NTM EBITDA of XXX

Genfit Stock Performance

Genfit has current market cap of $541M, and enterprise value of $600M.

Genfit's stock price is $10.81.

Genfit Valuation Multiples

Genfit trades at 7.2x EV/Revenue multiple, and (25.5x) EV/EBITDA.

Genfit Financial Valuation Multiples

As of April 19, 2026, Genfit has market cap of $541M and EV of $600M.

Equity research analysts estimate Genfit's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Genfit has a P/E ratio of (7.7x).

Genfit Margins & Growth Rates

Genfit's revenue in the last 12 month grew by 10%.

Genfit's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.8M for the same period.

Genfit's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Genfit's rule of X is 32% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Genfit Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Diagnostics & Genomics comps.

Genfit M&A Activity

Genfit acquired XXX companies to date.

Last acquisition by Genfit was on XXXXXXXX, XXXXX. Genfit acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Genfit Investment Activity

Genfit invested in XXX companies to date.

Genfit made its latest investment on XXXXXXXX, XXXXX. Genfit invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).